Compound ID	CDAMM00373
Common name	Cuscohygrine
IUPAC name	1-[(2S)-1-methylpyrrolidin-2-yl]-3-[(2R)-1-methylpyrrolidin-2-yl]propan-2-one
Molecular formula	C₁₃H₂₄N₂O

Experimental data

Retention time	58.972
Adduct	[M+H]+
Actual mz	225.199
Theoretical mz	225.196
Error	10.48
Ionizaton mode	Positive
Instrument type	LC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score	7.34

Identifiers and class information

Class
Inchi key	ZEBIACKKLGVLFZ-UHFFFAOYNA-N
Smiles	O=C(CC1N(C)CCC1)CC2N(C)CCC2
Superclass	Alkaloids and derivatives

Plant source

Moeroris amara (Schumach. & Thonn.) R.W.Bouman

Phyllanthus urinaria L.

External sources

HMDB ID	HMDB0030290
KNApSAcK ID	C00002034
FooDB ID	FDB002126
DrugBank ID
ChEBI ID	CHEBI:27920
Pubchem Compound ID	1201543
PlantCyc ID
UNPD ID	UNPD63663
Coconut ID
LipidMAPS ID
NANPDB ID

Pharmacokinetic properties

Number of descriptor values(#stars)	0
Number of non-conjugated amine groups (#amine)	2
Number of amidine and guanidine groups (#amidine)	0
Number of carboxylic acid groups (#acid)	0
Number of non-conjugated amide groups (#amide)	0
Number of rotatable bonds (#rotor)	4
Number of reactive functional groups (#rtvFG)	1
Predicted central nervous system activity (CNS)	2
Molecular weight (mol_MW)	224.345
Computed dipole moment(dipole)	1.86
Total solvent accessible surface area (SASA)	516.404
Hydrophobic component of SASA (FOSA)	491.782
Hydrophilic component of SASA (FISA)	24.622
Pie component of the SASA (PISA)	0
Weakly polar component of the SASA (WPSA)	0
Total solvent accesible volume (volume)	889.347
Number of hydrogen bond donors (donorHB)	0
Number of hydrogen bond acceptors (accptHB)	6
Free energy of solvation of dipole (dip^2/V)	0.0038881
Index of cohesive interaction in solids (ACxDN^.5/SA)	0
Globularity descriptor (glob)	0.866077
Predicted polarizability in cubic angstroms (QPpolrz)	26.869
Predicted hexadecane/gas partition coefficient (QPlogPC16)	6.666
Predicted octanol/gas partition coefficient (QPlogPoct)	11.031
Predicted water/gas partition coefficient (QPlogPw)	6.157
Predicted octanol/water partition coefficient (QPlogPo/w)	0.951
Predicted aqueous solubility (QPlogS)	0.229
Conformation-independent predicted aqueous solubility (CIQPlogS)	0.961
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)	-5.151
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)	359.919
Predicted brain/blood partition coefficient (QPlogBB)	0.901
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)	200.641
Predicted skin permeability, log Kp (QPlogKp)	-5.714
PM3 calculated ionization potential (IP(ev))	9.093
PM3 calculated electron affinity (EA(eV))	-0.729
Number of likely metabolic reactions (#metab)	4
Prediction of binding to human serum albumin (QPlogKhsa)	-0.575
Predicted qualitative human oral absorption (HumanOralAbsorption)	3
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)	78.264
Solvent-accessible surface area of fluorine atoms (SAFluorine)	0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)	0
Van der Waals surface area (PSA)	35.574
Number of nitrogen and oxygen atoms (#NandO)	3
Number of violations of Lipinski’s rule of five (RuleOfFive)	0
Number of violations of Jorgensen’s rule of three (RuleOfThree)	0

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID	Gene name	Target name	TTD_ID	Prediction source
P43681	CHRNA4	Neuronal acetylcholine receptor; alpha4/beta2	T70967	SEA
Q05940	SLC18A2	Synaptic vesicular amine transporter (by homology)	T48873	SEA
P32297	CHRNA3	Neuronal acetylcholine receptor; alpha3/beta4	T74166	SEA
P35367	HRH1	Histamine H1 receptor	T77913	SEA
P30926	CHRNB4	Neuronal acetylcholine receptor; alpha2/beta4	T73724	SEA
O95602	POLR1A	DNA-directed RNA polymerase I subunit RPA1	T89530	SEA
P17787	CHRNB2	Nicotinic acetylcholine receptor alpha2/beta2	T82543	SEA

Target associated diseases

TTD_ID	Disease_ID	Disease name	ICD_11	Uniprot ID	Gene names
T70967	DI0029	Aneurysm/dissection	[ICD-11: BD50]	P43681	CHRNA4
T70967	DI0191	Hypertensive crisis	[ICD-11: BA03]	P43681	CHRNA4
T70967	DI0196	Hypotension	[ICD-11: BA20-BA21]	P43681	CHRNA4
T48873	DI0079	Choreiform disorder	[ICD-11: 8A01]	Q05940	SLC18A2
T48873	DI0125	Dissociative neurological symptom disorder	[ICD-11: 6B60]	Q05940	SLC18A2
T48873	DI0129	Dystonic disorder	[ICD-11: 8A02]	Q05940	SLC18A2
T48873	DI0137	Essential hypertension	[ICD-11: BA00]	Q05940	SLC18A2
T48873	DI0190	Hypertension	[ICD-11: BA00-BA04]	Q05940	SLC18A2
T74166	DI0105	Cough	[ICD-11: MD12]	P32297	CHRNA3
T77913	DI0022	Allergic/hypersensitivity disorder	[ICD-11: 4A80-4A8Z]	P35367	HRH1
T77913	DI0033	Anxiety disorder	[ICD-11: 6B00-6B0Z]	P35367	HRH1
T77913	DI0063	Breathing abnormality	[ICD-11: MD11]	P35367	HRH1
T77913	DI0099	Conjunctiva disorder	[ICD-11: 9A60]	P35367	HRH1
T77913	DI0105	Cough	[ICD-11: MD12]	P35367	HRH1
T77913	DI0117	Depression	[ICD-11: 6A70-6A7Z]	P35367	HRH1
T77913	DI0136	Episodic vestibular syndrome	[ICD-11: AB31]	P35367	HRH1
T77913	DI0173	Headache	[ICD-11: 8A80-8A84]	P35367	HRH1
T77913	DI0214	Insomnia	[ICD-11: 7A00-7A0Z]	P35367	HRH1
T77913	DI0272	Morning sickness disorder	[ICD-11: SC00]	P35367	HRH1
T77913	DI0292	Nasopharyngitis	[ICD-11: CA00]	P35367	HRH1
T77913	DI0293	Nausea/vomiting	[ICD-11: MD90]	P35367	HRH1
T77913	DI0331	Parkinsonism	[ICD-11: 8A00]	P35367	HRH1
T77913	DI0349	Pruritus	[ICD-11: EC90]	P35367	HRH1
T77913	DI0366	Rheumatoid arthritis	[ICD-11: FA20]	P35367	HRH1
T77913	DI0388	Sleep-wake disorder	[ICD-11: 7A00-7B2Z]	P35367	HRH1
T77913	DI0432	Vasomotor/allergic rhinitis	[ICD-11: CA08]	P35367	HRH1
T73724	DI0301	Nicotine use disorder	[ICD-11: 6C4A]	P30926	CHRNB4
T82543	DI0301	Nicotine use disorder	[ICD-11: 6C4A]	P17787	CHRNB2